Second Line Breast Cancer Trial

AstraZeneca588 enrolled

Overview

The main purpose of this study is to compare the effect of 2 doses of FASLODEX with 1 dose of ARIMIDEX in terms of time to tumor progression in postmenopausal women with advanced breast cancer.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

588

Conditions

Advanced Breast Cancer

Interventions

FulvestrantDRUG

125mg

AnastrozoleDRUG

ARIMIDEX

FulvestrantDRUG

250mg

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * postmenopausal women with confirmation of breast cancer * objective evidence of recurrence or progression of breast cancer no more than 1 prior hormonal therapy for breast cancer Exclusion Criteria: * presence of life-threatening metastatic visceral disease * previous treatment with FASLODEX, ARIMIDEX or any aromatase inhibitor for breast cancer * more than 1 prior endocrine medical treatment for advanced breast cancer .

Outcomes

Primary Outcomes

time to tumor progression

Time frame: Every 3 months

Secondary Outcomes

objective tumor response

Time frame: Every 3 months

time to treatment failure

Time frame: Every 3 months

time to death

Time frame: Every 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.